Hormonal
Hypoglycemia occurs in approximately 9% of GLP-1/GIP RA emergency exposures, a rate higher than previously reported, even in the absence of concomitant hypoglycemic medications.
Be aware that GLP-1 medications can cause low blood sugar, even if you aren't taking insulin. This is more likely if you skip meals, exercise heavily, or take a higher dose. Monitor your blood sugar if you feel shaky, dizzy, or confused, and treat lows with fast-acting carbohydrates.
Hypoglycemia occurred in 9% of patients... hypoglycemia was observed at a higher rate than previously reported despite the absence of concomitant hypoglycemic agents.
Why this rating
Retrospective cohort study; consistent with prior poison center data but highlights a discrepancy in severity.
Source
Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department
H. Gärtner et al. · Annals of Pharmacotherapy · 2025
DOI 10.1177/10600280251334642
More from this paper
- Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.Good
- Semaglutide is associated with a higher incidence of symptomatic gastrointestinal adverse events compared to dulaglutide in the context of emergency exposures.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →